Key Points
- Ari Maizel, an Axsome insider, sold 7,500 shares on April 22 at an average price of $182.42, raising about $1,368,150 and reducing his ownership by 50% (he now owns 7,500 shares).
- Axsome recently beat quarterly EPS estimates (loss of $0.56 vs. est. $0.70) with revenue of $196M (up 65% YoY); the stock trades near $183, has a market cap of about $9.35B, and carries a consensus "Moderate Buy" rating with a ~$218 target.
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) insider Ari Maizel sold 7,500 shares of the stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $182.42, for a total value of $1,368,150.00. Following the completion of the transaction, the insider directly owned 7,500 shares of the company's stock, valued at approximately $1,368,150. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Axsome Therapeutics Stock Down 2.0%
Shares of NASDAQ:AXSM opened at $182.72 on Friday. The company has a quick ratio of 1.48, a current ratio of 1.55 and a debt-to-equity ratio of 1.38. The business has a fifty day moving average of $170.28 and a two-hundred day moving average of $159.70. The stock has a market cap of $9.35 billion, a P/E ratio of -49.52 and a beta of 0.48. Axsome Therapeutics, Inc. has a 52-week low of $96.09 and a 52-week high of $191.50.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Monday, February 23rd. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.14. The company had revenue of $196.00 million during the quarter, compared to analysts' expectations of $191.33 million. Axsome Therapeutics had a negative return on equity of 232.61% and a negative net margin of 28.69%.Axsome Therapeutics's revenue was up 65.0% on a year-over-year basis. On average, research analysts expect that Axsome Therapeutics, Inc. will post -1.25 earnings per share for the current year.
Analyst Upgrades and Downgrades
AXSM has been the subject of several recent research reports. TD Cowen reiterated a "buy" rating on shares of Axsome Therapeutics in a research note on Monday, February 23rd. Guggenheim lifted their price target on Axsome Therapeutics from $220.00 to $245.00 and gave the stock a "buy" rating in a research report on Wednesday, March 25th. Piper Sandler upped their price target on Axsome Therapeutics from $148.00 to $223.00 and gave the stock an "overweight" rating in a research note on Friday, January 16th. HC Wainwright upped their price target on Axsome Therapeutics from $200.00 to $260.00 and gave the stock a "buy" rating in a research note on Tuesday, January 20th. Finally, Jefferies Financial Group set a $215.00 price objective on Axsome Therapeutics in a report on Monday, February 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $218.06.
Check Out Our Latest Analysis on Axsome Therapeutics
Hedge Funds Weigh In On Axsome Therapeutics
Several large investors have recently added to or reduced their stakes in AXSM. Kemnay Advisory Services Inc. purchased a new position in shares of Axsome Therapeutics in the 4th quarter worth about $31,000. Ameriflex Group Inc. acquired a new position in shares of Axsome Therapeutics in the fourth quarter worth about $37,000. Versant Capital Management Inc raised its position in shares of Axsome Therapeutics by 20,300.0% in the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company's stock valued at $25,000 after purchasing an additional 203 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Axsome Therapeutics by 65.4% in the 4th quarter. GAMMA Investing LLC now owns 268 shares of the company's stock valued at $49,000 after purchasing an additional 106 shares in the last quarter. Finally, Farther Finance Advisors LLC raised its position in shares of Axsome Therapeutics by 602.6% in the 4th quarter. Farther Finance Advisors LLC now owns 274 shares of the company's stock valued at $50,000 after purchasing an additional 235 shares in the last quarter. 81.49% of the stock is currently owned by hedge funds and other institutional investors.
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome's pipeline includes several late-stage and approved product candidates.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
